269 related articles for article (PubMed ID: 37256921)
1. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
[TBL] [Abstract][Full Text] [Related]
2. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
4. Treatment of diabetic kidney disease. A network meta-analysis.
Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
8. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis.
Zhang L; Miao R; Yu T; Wei R; Tian F; Huang Y; Tong X; Zhao L
Pharmacol Res; 2022 Mar; 177():106111. PubMed ID: 35183713
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
11. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
Zhao J; Ai J; Mo C; Shi W; Meng L
Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
[TBL] [Abstract][Full Text] [Related]
14. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
Sun LJ; Sun YN; Shan JP; Jiang GR
J Diabetes Investig; 2017 Jul; 8(4):609-618. PubMed ID: 28107779
[TBL] [Abstract][Full Text] [Related]
15. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
16. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2023 Oct; 25(10):3020-3029. PubMed ID: 37435776
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
[TBL] [Abstract][Full Text] [Related]
19. Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.
Katsuhara Y; Ikeda S
Clin Drug Investig; 2021 Mar; 41(3):235-243. PubMed ID: 33564981
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
